GTx-758

GTx-758
Clinical data
Other namesCapesaris
Routes of
administration		By mouth
Legal status
Legal status
Identifiers
  • 3-fluoro-N-(4-fluorophenyl)-4-hydroxy-N-(4-hydroxyphenyl)benzamide
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H13F2NO3
Molar mass341.314 g·mol−1
3D model (JSmol)
  • C1=CC(=CC=C1N(C2=CC=C(C=C2)F)C(=O)C3=CC(=C(C=C3)O)F)O
  • InChI=1S/C19H13F2NO3/c20-13-2-4-14(5-3-13)22(15-6-8-16(23)9-7-15)19(25)12-1-10-18(24)17(21)11-12/h1-11,23-24H
  • Key:FBCQEUMZZNVQKD-UHFFFAOYSA-N

GTx-758 (tentative brand name Capesaris) is a synthetic nonsteroidal estrogen which was under development by GTx, Inc. for the treatment of advanced prostate cancer.[1] As of 2016, it had completed two phase II clinical trials.[2]

  1. ^ Coss CC, Jones A, Parke DN, Narayanan R, Barrett CM, Kearbey JD, et al. (March 2012). "Preclinical characterization of a novel diphenyl benzamide selective ERα agonist for hormone therapy in prostate cancer". Endocrinology. 153 (3): 1070–1081. doi:10.1210/en.2011-1608. PMID 22294742.
  2. ^ "GTX 758". AdisInsight. Springer Nature Switzerland AG.